Quantcast
Last updated on April 19, 2014 at 1:20 EDT

Latest placebo Stories

2013-12-11 08:31:07

--Ongoing CUPID 2 Study Potential to Serve as Primary Basis of Efficacy and Safety Required for MMA Submission in European Union-- SAN DIEGO, Dec. 11, 2013 /PRNewswire/ -- Celladon Corporation, a clinical-stage biotechnology company focused on developing novel therapies by applying its leadership position in the field of SERCA enzymes, today announced that the Company has received requested scientific advice from the Committee for Medicinal Products for Human Use (CHMP) of the...

2013-12-09 08:28:41

- Findings Show Positive Trends in Slowing Advancement of Disease, as well as Enhanced Activity of NP001 in Patients with Increased Baseline Inflammation - PALO ALTO, Calif., Dec. 9, 2013 /PRNewswire/ -- Neuraltus Pharmaceuticals, Inc. announced today that promising efficacy results of the Company's Phase 2 clinical program of NP001 for the treatment of amyotrophic lateral sclerosis (ALS, or Lou Gehrig's disease) were highlighted in an oral presentation at the 24th International...

2013-12-06 15:03:36

Women with moderate to severe menstrual cramps may find relief in a class of erectile dysfunction drugs, according to a team of researchers led by Penn State College of Medicines Richard Legro. Primary dysmenorrhea, also called PD, is the most common cause of pelvic pain in women. The current treatment is non-steroidal anti-inflammatory drugs, such as ibuprofen. However, ibuprofen does not work well for all women, and can be associated with ulcers and kidney damage when used chronically as...

2013-12-05 20:22:00

LEXINGTON, Massachusetts, December 5, 2013 /PRNewswire/ -- Shire plc (LSE: SHP, NASDAQ: SHPG), the global specialty biopharmaceutical company, today announced top-line results from OPUS-2, a Phase 3 efficacy and safety study of 5.0% lifitegrast ophthalmic solution. OPUS-2 compared lifitegrast to placebo administered twice daily for 84 days (12 weeks) in dry eye patients with history of active artificial tear use within 30 days prior to screening. Lifitegrast met the...

Tuberculosis Vaccine Cure For MS
2013-12-05 11:34:05

Brett Smith for redOrbit.com - Your Universe Online A new preliminary study from a team of Italian researchers has found that a vaccine used to thwart tuberculosis outside the US could be used to treat multiple sclerosis (MS). In the study, which was published in the journal Neurology, scientists found people who had early symptoms of MS and MRI scans pointing to the development of the neurological condition benefited from receiving an injection of Bacille Calmette-Guérin, which is...

2013-12-05 08:29:48

WOODCLIFF LAKE, N.J., Dec. 5, 2013 /PRNewswire/ -- Today, Eisai Inc. announced that 16 abstracts highlighting new data analyses on FYCOMPA (perampanel) will be presented at the 67(th) annual American Epilepsy Society (AES) meeting, taking place in Washington, D.C. from December 6 - 10. (Logo: http://photos.prnewswire.com/prnh/20120413/MM87168LOGO) "These data analyses highlight Eisai's clinical research with FYCOMPA, reinforcing our commitment to the epilepsy community," said Lynn Kramer,...

2013-12-03 08:31:24

THE WOODLANDS, Texas, Dec. 3, 2013 /PRNewswire/ -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced top-line results from an initial Phase 2 study exploring the use of LX1033 in diarrhea-predominant irritable bowel syndrome (IBS-d). LX1033 is an investigational drug that inhibits serotonin synthesis in the gastrointestinal tract. Serotonin is a neurotransmitter that has been shown to play a role in the symptoms of irritable bowel syndrome. The primary endpoint of this...

2013-11-29 12:54:05

Scientists may have found a new treatment that can help people with spinal cord injuries walk better. The research is published in the November 27, 2013, online issue of Neurology®, the medical journal of the American Academy of Neurology. "About 59 percent of all spinal injuries are incomplete, leaving pathways that could allow the spinal cord to change in a way that allows people to walk again. Unfortunately, usually a person affected by this type of spinal injury seldom recovers the...

2013-11-27 15:06:57

Among children and adolescents with Crohn disease not responding to treatment, use of the drug thalidomide resulted in improved clinical remission after 8 weeks of treatment compared with placebo, according to a study appearing in the November 27 issue of JAMA. As many as 1.2 million people in Europe and more than half a million in the United States are estimated to have Crohn disease, a chronic inflammatory disease involving the digestive system. Its incidence is increasing globally....

2013-11-26 08:27:58

NEW YORK, Nov. 26, 2013 /PRNewswire/ -- Mercy Nutraceuticals, Inc., the maker of functional products for health-conscious consumers, is pleased to announce the preliminary results of a clinical study showing that its hangover-prevention supplement Mercy reduces symptoms associated with alcohol consumption. As the industry leader in hangover prevention, Mercy Nutraceuticals is committed to improving the health and well-being of consumers and believes that responsible adults should not...